Clinical trials: Major Depressive Disorder, completed
Unipolar Major Depression
Theta Burst Study Ghent
50 Right-handed antidepressant-free unipolar depressed patients (age 18-65 years) will be treated with in total 20 Theta burst sessions; these will be spread over 4 days.
- Trial name
- TBS Ghent (NCT01832805)
- Testing
- Theta burst stimulation.
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Ghent
Major Depressive Disorder
Development of Pregnenolone as a Treatment for Depression
Pregnenolone, an over-the-counter supplement, is a naturally occurring neurosteroid made in the adrenal glands and brain. Preclinical research suggests pregnenolone has antidepressant, cognitive enhancing, and neuroprotective…
- Trial name
- NCT03645096
- Testing
- Pregnenolone 500 mg, Pregnenolone 800 mg
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Texas Southwestern Medical Center
Healthy
A Multiple Ascending Dose Study of BCI-838 in Healthy Volunteers
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BCI-838 and its metabolite BCI-632 in healthy male and female subjects.
- Trial name
- NCT01548703
- Testing
- BCI-838
- Where
- Netherlands
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- BrainCells Inc.
Depressive Disorder, Major
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
The purpose of this study is to evaluate the efficacy of intranasal esketamine 84 milligram (mg) compared with intranasal placebo in addition to comprehensive standard of care in reducing the symptoms of Major Depressive Disorder…
- Trial name
- Aspire II (NCT03097133)
- Testing
- Esketamine, Standard of Care
- Where
- 61 sites in United States, Argentina and 10 more
- Volunteers
- 230 people
- Sponsor
- Janssen Research & Development, LLC
Suicidal Ideation, Major Depressive Disorder
Sequential Bilateral Accelerated Theta Burst Stimulation in Adolescents With Suicidal Ideation
The purpose of this study is to gather information regarding the use of a new type of transcranial magnetic stimulation (TMS) called theta burst stimulation (TBS) for suicidal ideation in adolescents with Major Depressive…
- Trial name
- NCT04502758
- Testing
- MagVenture TMS Therapy System w/Theta Burst Stimulation
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Mayo Clinic
Depression, Anxiety
Clinical and Cost Effectiveness of Brief Cognitive-Behavioral Therapy (CBT) for Pediatric Internalizing Disorders
This project assesses the clinical and cost effectiveness of brief cognitive-behavioral therapy (CBT) for depressed (ages 11-17) and anxious (ages 8-17) youths seen for services in pediatric primary care.
- Trial name
- NCT00669526
- Testing
- BCBT, SMHC referral
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Robert Wood Johnson Foundation
Major Depressive Disorder, Post-traumatic Stress Disorder
Cognitive Training Program for Individuals With Depression and Post-Traumatic Stress Disorder
Individuals with affective disorders (including post-traumatic stress disorder (PTSD) and major depressive disorder (MDD)) often experience declines in cognitive abilities such as memory and attention.
- Trial name
- NCT02502604
- Testing
- Goal Management Training
- Where
- Canada
- Volunteers
- 58 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Major Depressive Disorder
ALTO-300 in Depression
The purpose of this study is to collect biologically-based data for defining predictors and correlates of the effects of ALTO-300.
- Trial name
- NCT05118750
- Testing
- ALTO-300 oral (PO) tablet
- Where
- 11 sites in United States
- Volunteers
- 91 people
- Sponsor
- Alto Neuroscience
Major Depressive Disorder, Bipolar I Disorder
Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.
Depression and suicidal ideation/attempt/death are major causes of morbidity and mortality from psychiatric illnesses. In 2009, the World Health Organization listed depression as the leading cause of years lost due to disability…
- Conditions
- Major Depressive Disorder, Bipolar I Disorder, Bipolar II Disorder, Bipolar Depression
- Trial name
- NCT02593643
- Testing
- Ketamine, Midazolam, Treatment as usual (TAU)
- Where
- Canada
- Volunteers
- 9 people
- Sponsor
- Sunnybrook Health Sciences Centre
Depression, Depressive Disorder
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of TNX-601 ER monotherapy versus placebo in patients with Major Depressive Disorder (MDD).
- Conditions
- Depression, Depressive Disorder, Depressive Symptoms, Depressive Disorder, Major
- Trial name
- UPLIFT (NCT05686408)
- Testing
- TNX-601 ER
- Where
- 27 sites in United States
- Volunteers
- 132 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Major Depressive Disorder (MDD)
Electrophysiological Biomarkers in Accelerated TMS for Depression
This study investigates whether physiological signals recorded during transcranial magnetic stimulation (TMS) can predict which patients with major depression respond to treatment.
- Trial name
- NCT07615387
- Testing
- Accelerated bilateral dmPFC-iTBS
- Where
- Turkey (Türkiye)
- Volunteers
- 32 people
- Sponsor
- Istanbul University - Cerrahpasa
Insomnia, Depression
Acupuncture for Persistent Insomnia Associated With Major Depressive Disorder
The purpose of this study is to evaluate the clinical effectiveness of acupuncture treatment on residual insomnia in major depressive patients.
- Trial name
- NCT01707706
- Testing
- Acupuncture
- Where
- Hong Kong
- Volunteers
- 150 people
- Sponsor
- The University of Hong Kong
Major Depressive Disorder
Efficacy of Adjunctive Exercise for the Behavioral Treatment of Major Depression
Major depressive disorder (MDD) is the leading cause of disability in the developed world and is associated with lost productivity, increased health care utilization, and mortality.
- Trial name
- NCT02176408
- Testing
- Behavioral Activation, Exercise Intervention, Stretching Intervention
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Boston University Charles River Campus
Depression, Major Depressive Disorder
Stress Generation and Recurrent Depression: The Role of Differential Treatment Response
Depression affects over one million people in Canada, resulting in $14.4 billion per year in costs to Canadian society. In order to prevent this often lifelong disorder, it is critically important to identify risk factors for the…
- Trial name
- NCT00745017
- Testing
- Cognitive Behavioral Therapy, Interpersonal Therapy, Antidepressant medication
- Where
- Canada
- Volunteers
- 72 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD)
Impact of Anxiety and Depression on Implicit and Explicit Memory Performance
This study examines the effect of anxiety and depression on memory processes, focusing on implicit and explicit memory. Implicit memory involves unconscious recall, such as recognizing familiar words without effort, while…
- Conditions
- Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Memory Bias, Implicit Memory
- Trial name
- ADEM (NCT06663423)
- Where
- Iran
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Islamic Azad University, Sanandaj
Depression
Major Depressive Disorder (MDD)
The purpose of this study is to assess the effectiveness of systematic screening for depression in high-risk patient participants in everyday clinical practice.
- Trial name
- NCT01662817
- Testing
- Intervention, Control
- Where
- Spain
- Volunteers
- 525 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major
PRJ2215: Assessment of Buproprion Misuse/Abuse 2004-2011
Bupropion hydrochloride was first approved on 30 December 1985 in United States for depression and is currently approved in 80 countries.
- Trial name
- NCT02039960
- Testing
- Bupropion
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Depressive Disorder, Major
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
Evaluating the efficacy of vortioxetine 10 mg/day and 20 mg/day versus placebo on depressive symptoms in adolescents (age ≥12 and ≤17 years) with a DSM-5™ (Diagnostic and Statistical Manual of Mental Disorders, 5th edition)…
- Trial name
- NCT02709746
- Testing
- Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20 mg/day
- Where
- 124 sites in United States, Bulgaria and 17 more
- Volunteers
- 784 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder, Bipolar I and Bipolar II
Microbiome of Depression & Treatment Response to Citalopram
The purpose of this study is to evaluate the feasibility of developing a microbiome probe of depression and to evaluate the microbiome change in a preliminary analysis of treatment response (n=20) vs.
- Trial name
- NCT02330068
- Testing
- citalopram
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Depression, Depressive Disorders
A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845)
The primary purpose of this study is to determine whether subjects with psychotic major depression benefit from adjunctive treatment with Org 34517.
- Conditions
- Depression, Depressive Disorders, Psychotic Disorders
- Trial name
- Hermes (NCT00212797)
- Testing
- Org 34517
- Volunteers
- 273 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.